The UK aesthetic injectable market has undergone a significant shift over the past decade. Korean-manufactured aesthetic products — botulinum toxins, hyaluronic acid fillers and skin boosters, PDRN polynucleotides, lipolytic agents, and now exosomes — have moved from being unfamiliar imports to becoming the preferred clinical tools of a growing proportion of UK aesthetic practitioners.

Two of the most clinically significant injectable categories in modern aesthetic medicine — polynucleotides/PDRN and exosomes — are frequently compared by practitioners trying to determine which to offer, which to prioritise for specific patients, and whether there is clinical value in using both. The comparison is worth making carefully, because the two treatments operate through genuinely different mechanisms, have different evidence bases, suit different patient profiles in some respects, and produce their best outcomes in different clinical contexts.

The aesthetic exosome market is growing rapidly and unevenly. Alongside genuinely well-characterised, rigorously manufactured Korean products with transparent documentation, the market contains preparations making compelling regenerative claims while providing minimal evidence of their actual content, source, or regulatory classification. For practitioners, the ability to evaluate exosome products on scientific and regulatory grounds is essential.